The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Significance of Cross-Linking of α2-Plasmin Inhibitor to Fibrin in Inhibition of Fibrinolysis and in Hemostasis
Open accessAbstract
When blood is clotted, alpha(2)-plasmin inhibitor (alpha(2)PI) is cross-linked to fibrin by activated fibrin-stabilizing factor (activated coagulation Factor XIII, plasma transglutaminase). The amount of cross-linked alpha(2)-PI is proportional to the amount of alpha(2)PI present at the time of clotting. Plasma from a patient with congenital deficiency of alpha(2)PI was supplemented with various amounts of purified alpha(2)PI. Clots were prepared from these plasmas and were suspended in plasma containing a normal concentration of alpha(2)PI, and spontaneous clot lysis was observed. When the clot was formed in the presence of calcium ions and thereby allowing cross-linking to occur, the rate and extent of fibrinolysis were found to be inversely proportional to the concentrations of alpha(2)PI present in the clot at the time of clotting. When the clot was formed in the absence of calcium ions so that no cross-linking occurred, the clot underwent fibrinolysis at similar rates, regardless of the concentrations of alpha(2)PI in the clot. When the clot formed in the presence of calcium ions was squeezed and washed to remove unbound proteins before being suspended in plasma, the extent of fibrinolysis was also inversely proportional to the amount of alpha(2)PI cross-linked to fibrin. Similar results were obtained when the clot was suspended in buffered saline instead of plasma. These observations suggest that spontaneous fibrinolysis is mainly carried out by plasminogen/plasminogen activator bound to fibrin, and this fibrinolysis caused by fibrin-associated activation of plasminogen was mainly inhibited by alpha(2)PI cross-linked to fibrin. To further support this concept, alpha(2)PI treated with activated fibrin-stabilizing factor and that had lost most of its cross-linking capacity was used in similar experiments. This modified alpha(2)PI had the same inhibitory activity on plasmin as the native inhibitor, but gave significantly less inhibition of fibrinolysis in every experiment, particularly when the clot was compacted by platelet-mediated clot retraction or by squeezing. Thus, it was concluded that alpha(2)PI cross-linked to fibrin plays a significant role in inhibition of physiologically occurring fibrinolysis. It is further suggested that the absence of cross-linked alpha(2)PI contributes to accelerated fibrinolysis and hemorrhagic tendency in patients with congenital deficiency of fibrin-stabilizing factor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weber, K., & Osborn, M. (1969) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)94333-4 · Cited by 20,298
Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor
Mosher, D. (1975) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)41110-1 · Cited by 566
Human Factor XIII from Plasma and Platelets
Schwartz, M. L., Pizzo, S. V., Hill, R. L., & McKee, P. A. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)44312-3 · Cited by 439
Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.
Sakata, Y., & Aoki, N. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109671 · Cited by 396
Self-citationIdentification and Some Properties of a New Fast‐Reacting Plasmin Inhibitor in Human Plasma
COLLEN, D. (1976) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1976.tb10875.x · Cited by 338
Congenital Deficiency of α2-Plasmin Inhibitor Associated with Severe Hemorrhagic Tendency *
Aoki, N., Saito, H., Kamiya, T., Koie, K., Sakata, Y., & Kobakura, M. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109387 · Cited by 197
Self-citationCross-linking of α2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor
Tamaki, T., & Aoki, N. (1981) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(81)90016-4 · Cited by 106
Self-citation[15] Fibrin-stabilizing factor (factor XIII)
Curtis, C. G., & Lorand, L. (1976) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(76)45018-8 · Cited by 98
Influence of α2-plasmin inhibitor on adsorption of plasminogen to fibrin
Aoki, N., & Sakata, Y. (1980) · Thrombosis Research · doi:10.1016/0049-3848(80)90414-4 · Cited by 31
Self-citation
Cited by
Fibrinogen and fibrin structure and functions
MOSESSON, M. W. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01365.x · Cited by 1,695
Apoptosis: Mechanisms and Roles in Pathology
ARENDS, M. J., & WYLLIE, A. H. (1991) · International Review of Experimental Pathology · doi:10.1016/b978-0-12-364932-4.50010-1 · Cited by 1,334
The Structure and Biological Features of Fibrinogen and Fibrin
MOSESSON, M. W., SIEBENLIST, K. R., & MEH, D. A. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03491.x · Cited by 627
Factor XIII: A Coagulation Factor With Multiple Plasmatic and Cellular Functions
Muszbek, L., Bereczky, Z., Bagoly, Z., Komáromi, I., & Katona, É. (2011) · Physiological Reviews · doi:10.1152/physrev.00016.2010 · Cited by 493
Platelets and Thrombolytic Therapy
Coller, B. S. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220107 · Cited by 482
Metadata
- Authors
- Sakata, Y., & Aoki, N.
- Venue
- Journal of Clinical Investigation
- Published
- 1982-03-01
- Volume
- 69
- Issue
- 3
- Pages
- 536-542
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1991243300
- Cited by
- 288
- References
- 9
- FWCI
- 15.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.